Meyahealth
HomeGeneticsGeneGRIN2B gene
Back to Gene
GRIN2B gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GRIN2B gene

The GRIN2B gene provides instructions for the GluN2B protein, a key component of NMDA receptors involved in brain development and neuronal maturation.

Normal Function

The GRIN2B gene provides instructions for making a protein called GluN2B. This protein is found in nerve cells (neurons) in the brain, primarily during development before birth. The GluN2B protein is one component (subunit) of a subset of specialized protein structures called NMDA receptors. These receptors are glutamate-gated ion channels that, when activated by glutamate and glycine, allow cations to flow into the cell. This flow excites neurons to send signals and plays a role in the process by which neurons mature (differentiation). NMDA receptors are involved in normal brain development, synaptic plasticity, learning, and memory.

Health Conditions Related to Genetic Changes

GRIN2B-related neurodevelopmental disorder

Several dozen mutations in the GRIN2B gene have been found to cause GRIN2B-related neurodevelopmental disorder, which is characterized by intellectual disability and delayed development of speech and motor skills. Other neurological problems that commonly occur include seizures, weak muscle tone (hypotonia), movement disorders, and behavioral problems.

Many GRIN2B gene mutations lead to production of a nonfunctional GluN2B protein or prevent the production of any GluN2B protein from one copy of the gene. A shortage of this protein may reduce the number of functional NMDA receptors. Other mutations lead to the production of abnormal GluN2B proteins that alter how the NMDA receptors function; some mutations reduce NMDA receptor signaling while others increase it. Researchers are currently studying how abnormal activity of NMDA receptors prevents normal growth and development of the brain.

Other Names for This Gene

  • GluN2B
  • glutamate [NMDA] receptor subunit epsilon-2
  • glutamate receptor ionotropic, NMDA 2B precursor
  • glutamate receptor subunit epsilon-2
  • glutamate receptor, ionotropic, N-methyl D-aspartate 2B
  • hNR3
  • N-methyl D-aspartate receptor subtype 2B
  • NMDAR2B
  • NR2B

Frequently Asked Questions

Mutations that reduce or alter GluN2B function impair synaptic plasticity, leading to delayed speech and motor milestones. Early, intensive speech therapy, occupational therapy, and physical therapy can harness neuroplasticity, often improving communication and motor skills. Early intervention programs, ideally starting before 12 months, are associated with better developmental trajectories.
Seizure management follows standard epilepsy protocols, but clinicians often consider NMDA receptor modulators. Low-dose memantine, an NMDA antagonist, has been used off-label to reduce hyperexcitability in some patients, though evidence is limited. Antiepileptic drugs (e.g., valproate, levetiracetam) remain first-line. A multidisciplinary team—including neurologists, geneticists, and neuropsychologists—is crucial for individualized therapy.
Prognosis varies with mutation type and severity. Many individuals experience persistent intellectual disability and motor challenges, but many also achieve meaningful independence with support. Cognitive and behavioral therapies can mitigate social and emotional difficulties. Regular monitoring for seizures, sleep disturbances, and growth is recommended throughout life.
comprehensive evaluation typically starts with a detailed developmental history and physical exam, followed by neuroimaging (MRI) to rule out structural brain anomalies. Genetic testing is essential—whole-exome sequencing or targeted GRIN2B sequencing can identify pathogenic variants. Functional studies, such as electrophysiological assays of patient-derived cells, may be used in research settings to assess receptor activity. Early diagnosis allows for timely intervention planning.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ